Myoepithelial Markers in Breast Tissue
The most commonly used and reliable myoepithelial markers in breast pathology include smooth muscle myosin heavy chains, calponin, p63, α-smooth muscle actin (α-SMA), cytokeratin 5/6 (CK5/6), CD10, maspin, and P-cadherin 1.
Recommended Panel Approach
A panel-based approach using 2 or more markers is essential for accurate myoepithelial cell identification, as no single marker demonstrates both perfect sensitivity and specificity 1. The optimal combination includes:
First-Line Markers (High Sensitivity & Specificity):
- Smooth muscle myosin heavy chains - excellent sensitivity and specificity
- Calponin - highly sensitive for normal and neoplastic myoepithelial cells 2
- p63 - highly sensitive, though may show reduced expression around in situ carcinomas 1
- α-SMA (α-smooth muscle actin) - significantly more sensitive than high-molecular weight cytokeratins 2
Supplementary Markers:
- CK5/6 and CK14 (high-molecular weight cytokeratins) - useful but show variable sensitivity depending on lesion type 2
- CD10 - consistent expression across lesion types 2
- p75, P-cadherin, maspin - provide complementary information 1
Critical Diagnostic Considerations
Normal Tissue Controls
Normal breast myoepithelial cells must show diffuse and strong positivity with a heterogeneous staining pattern displaying weak, moderate, and intense immunoreactivity 3. Myoepithelial cells and stromal cells must be invariably negative as internal negative controls 3.
Key Pitfalls to Avoid
Reduced Expression in DCIS: Myoepithelial markers show variably reduced expression in cells bordering ductal carcinoma in situ, which can lead to false-negative interpretations 1.
Stromal Cross-Reactivity: Many markers (particularly α-SMA, calponin, CD10) show cross-reactivity with myofibroblasts and vascular smooth muscle, potentially causing false-positive interpretations 1.
Paradoxical Staining in Clear Cell Lesions: High-molecular weight cytokeratins show a unique pattern with diffusely positive inner epithelial cells but completely negative outer myoepithelial cells in clear cell adenomyoepithelioma 2.
Tumor Cell Positivity: p63 can be expressed in 70-95% of urothelial carcinomas and 86% of poorly differentiated squamous cell carcinomas, and CK5/6 is positive in triple-negative breast carcinomas 4, 5.
Specific Clinical Applications
Distinguishing Invasive from In Situ Disease
- Benign and in situ lesions: Retain myoepithelial cell layer
- Invasive carcinomas: Lack surrounding myoepithelial cells 6
- Exception: Some benign sclerosing lesions show partial or complete absence of myoepithelial layer 7
Adenomyoepithelioma Diagnosis
The optimal panel combines high-molecular weight cytokeratins (CK5/6 or CK14) with any one of α-SMA, calponin, or p63 2. This combination capitalizes on the unique paradoxical staining pattern of HMWCK while ensuring adequate sensitivity.
p40 as an Alternative to p63
p40 performs similarly to p63 for myoepithelial identification in normal structures and most breast lesions, with parallel focal losses of expression 5. However, p40 shows more frequent and marked staining in CK5-positive triple-negative carcinomas (18/19 vs 8/19 for p63), making it potentially superior in this specific context 5.
Practical Implementation Strategy
Start with a dual-marker panel: Combine one contractile marker (smooth muscle myosin heavy chains, calponin, or α-SMA) with one nuclear marker (p63 or p40)
Evaluate internal controls first: Confirm normal myoepithelial cells show expected heterogeneous positivity and stromal cells are negative
Add supplementary markers if equivocal: Use CK5/6, CD10, or maspin when initial panel shows ambiguous results
Always correlate with morphology: Immunohistochemistry is supplemental, not central, to routine morphologic interpretation 1